tetano
Editor, Senior Moderator
Nat Med
. 2021 Jul 14.
doi: 10.1038/s41591-021-01449-9. Online ahead of print.
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros-Martins[SUP] #[/SUP][SUP] 1 [/SUP], Swantje I Hammerschmidt[SUP] #[/SUP][SUP] 1 [/SUP], Anne Cossmann[SUP] #[/SUP][SUP] 2 [/SUP], Ivan Odak[SUP] 1 [/SUP], Metodi V Stankov[SUP] 2 [/SUP], Gema Morillas Ramos[SUP] 2 [/SUP], Alexandra Dopfer-Jablonka[SUP] 2 3 [/SUP], Annika Heidemann[SUP] 2 [/SUP], Christiane Ritter[SUP] 1 [/SUP], Michaela Friedrichsen[SUP] 1 [/SUP], Christian Schultze-Florey[SUP] 1 4 [/SUP], Inga Ravens[SUP] 1 [/SUP], Stefanie Willenzon[SUP] 1 [/SUP], Anja Bubke[SUP] 1 [/SUP], Jasmin Ristenpart[SUP] 1 [/SUP], Anika Janssen[SUP] 1 [/SUP], George Ssebyatika[SUP] 5 [/SUP], Günter Bernhardt[SUP] 1 [/SUP], Jan Münch[SUP] 6 [/SUP], Markus Hoffmann[SUP] 7 8 [/SUP], Stefan Pöhlmann[SUP] 7 8 [/SUP], Thomas Krey[SUP] 5 9 [/SUP], Berislav Bošnjak[SUP] 10 [/SUP], Reinhold Förster[SUP] 11 12 13 [/SUP], Georg M N Behrens[SUP] 14 15 16 [/SUP]
Affiliations
Abstract
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer's BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.
. 2021 Jul 14.
doi: 10.1038/s41591-021-01449-9. Online ahead of print.
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
Joana Barros-Martins[SUP] #[/SUP][SUP] 1 [/SUP], Swantje I Hammerschmidt[SUP] #[/SUP][SUP] 1 [/SUP], Anne Cossmann[SUP] #[/SUP][SUP] 2 [/SUP], Ivan Odak[SUP] 1 [/SUP], Metodi V Stankov[SUP] 2 [/SUP], Gema Morillas Ramos[SUP] 2 [/SUP], Alexandra Dopfer-Jablonka[SUP] 2 3 [/SUP], Annika Heidemann[SUP] 2 [/SUP], Christiane Ritter[SUP] 1 [/SUP], Michaela Friedrichsen[SUP] 1 [/SUP], Christian Schultze-Florey[SUP] 1 4 [/SUP], Inga Ravens[SUP] 1 [/SUP], Stefanie Willenzon[SUP] 1 [/SUP], Anja Bubke[SUP] 1 [/SUP], Jasmin Ristenpart[SUP] 1 [/SUP], Anika Janssen[SUP] 1 [/SUP], George Ssebyatika[SUP] 5 [/SUP], Günter Bernhardt[SUP] 1 [/SUP], Jan Münch[SUP] 6 [/SUP], Markus Hoffmann[SUP] 7 8 [/SUP], Stefan Pöhlmann[SUP] 7 8 [/SUP], Thomas Krey[SUP] 5 9 [/SUP], Berislav Bošnjak[SUP] 10 [/SUP], Reinhold Förster[SUP] 11 12 13 [/SUP], Georg M N Behrens[SUP] 14 15 16 [/SUP]
Affiliations
- PMID: 34262158
- DOI: 10.1038/s41591-021-01449-9
Abstract
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca's ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School's COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer's BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4[SUP]+[/SUP] and CD8[SUP]+[/SUP] T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2.